icon-folder.gif   Conference Reports for NATAP  
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom  April 9-13
Back grey_arrow_rt.gif
Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter Study
  Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Didier Samuel,1 Michael Charlton,2 Edward Gane,3 Robert S. Brown Jr,4 Michael P. Curry,5 Paul Kwo,6 Robert Fontana,7 Richard Gilroy,8 Lewis Teperman,9 Andrew J. Muir,10 John G. McHutchison,11 William T. Symonds,11 Jill Denning,11 Lindsay McNair,11 Sarah Arterburn,11 Norah Terrault,12 Xavier Forns,13 Michael P. Manns14
1Université Paris Sud, Villejuif, France; 2Intermountain Medical Center, Murray, Utah, USA; 3Auckland City Hospital, Auckland, New Zealand; 4Columbia University, New York, New York, USA; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; 6Indiana University School of Medicine, Indianapolis, Indiana, USA; 7University of Michigan, Ann Arbor, Michigan, USA; 8Kansas University Medical Center, Lawrence, Kansas, USA; 9NYU Medical Center, New York, New York, USA; 10Duke University Medical Center, Durham, North Carolina, USA; 11Gilead Sciences, Inc., Foster City, California, USA; 12University of California, San Francisco, California; 13The Liver Unit, Hospital Clinic, Barcelona, Spain; 14Hannover Medical School, Hannover, Germany
AASLD/2013: Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection After Liver
Transplantation......http://www.natap.org/2013/AASLD/AASLD_31.htm......."number of consecutive days with HCV RNA TND prior to transplant appears to be the strongest predictor of pTVR (post transplant virology response)"